Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin, Margaret K Callahan, Boyu Ren, Raya Khanin, Agnes Viale, Lilan Ling, Daniel No, Asia Gobourne, Eric Littmann, Curtis Huttenhower, Eric G Pamer, Jedd D Wolchok, Krista Dubin, Margaret K Callahan, Boyu Ren, Raya Khanin, Agnes Viale, Lilan Ling, Daniel No, Asia Gobourne, Eric Littmann, Curtis Huttenhower, Eric G Pamer, Jedd D Wolchok
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Figures
References
- Caballero S. & Pamer E. G. Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu. Rev. Immunol. 33, 227–256 (2015).
- Belkaid Y. & Hand T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).
- Qin J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
- Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
- Atarashi K. et al. Induction of colonic regulatory T cells by indigenous clostridium species. Science 331, 337–341 (2011).
- Mazmanian S. K., Liu C. H., Tzianabos A. O. & Kasper D. L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107–118 (2005).
- Sokol H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of crohn disease patients. Proc. Natl Acad. Sci. 105, 16731–16736 (2008).
- Lupp C. et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae. Cell Host Microbe 2, 119–129 (2007).
- Stecher B. et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol. 5, 2177–2189 (2007).
- Winter S. E. et al. Host-derived nitrate boosts growth of E. Coli in the inflamed gut. Science 339, 708–711 (2013).
- Hodi F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
- Berman D. et al. Blockade of cytotoxic t-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 10, 11–21 (2010).
- Weber J. S. et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119, 1675–1682 (2013).
- Lord J. D. et al. Refractory colitis following anti-ctla4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig. Dis. Sci. 55, 1396–1405 (2010).
- Gupta A, De Felice K.M., Loftus E.V. & Khanna S. Systematic review: colitis associated with anti-ctla-4 therapy. Aliment. Pharmacol. Ther. 42, 406–417 (2015).
- Round J. L. & Mazmanian S. K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl Acad. Sci. USA 107, 12204–12209 (2010).
- Faith J. J., Ahern P. P., Ridaura V. K., Cheng J. & Gordon J. I. Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci. Transl. Med. 6, 220ra11 (2014).
- Hill M. J. Intestinal flora and endogenous vitamin synthesis. Eur. J. Cancer Prev. 6, S43–S45 (1997).
- Gill S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355–1359 (2006).
- Coates M. E., Ford J. E. & Harrison G. F. Intestinal synthesis of vitamins of the B complex in chicks. Br. J. Nutr. 22, 493–500 (1968).
- Kuroki F. et al. Multiple vitamin status in crohn's disease. Dig. Dis. Sci. 38, 1614–1618 (1993).
- Ellestad-Sayed J. J., Nelson R. A., Adson M. A., Palmer W. M. & Soule E. H. Pantothenic acid, coenzyme A, and human chronic ulcerative and granulomatous colitis. Am. J. Clin. Nutr. 29, 1333–1338 (1976).
- Kjer-Nielsen L. et al. (2012) MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717–723.
- Serriari N. E. et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin. Exp. Immunol. 176, 266–274 (2014).
- Furuchi T., Kashiwagi K., Kobayashi H. & Igarashi K. Characteristics of the gene for a spermidine and putrescine transport system that maps at 15 min on the escherichia coli chromosome. J. Biol. Chem. 266, 20928–20933 (1991).
- Ricci G. et al. Ornithine decarboxylase in colonic mucosa from patients with moderate or severe Crohn's disease and ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 11, 903–904 (1999).
- Weiss T. S. et al. Intracellular polyamine levels of intestinal epithelial cells in inflammatory bowel disease. Inflamm. Bowel Dis. 10, 529–535 (2004).
- Topalian S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030 (2014).
- Sivan A. et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-pd-l1 efficacy. Science 350, 1084–1089 (2015).
- Vétizou M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).
- Iida N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).
- Viaud S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–976 (2013).
- Schloss P. D. et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537–7541 (2009).
- Edgar R. C., Haas B. J., Clemente J. C., Quince C & Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27, 2194–2200 (2011).
- Abubucker S. et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput. Biol. 8, e1002358 (2012).
- Kanehisa M., Goto S., Furumichi M., Tanabe M. & Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355–D360 (2010).
- Segata N. et al. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat. Methods 9, 811–814 (2012).
- Segata N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
Source: PubMed